Home » Stocks » Kamada

Kamada Ltd. (KMDA)

Stock Price: $8.73 USD -0.29 (-3.22%)
Updated Aug 4, 2020 12:42 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 388.66M
Revenue (ttm) 133.68M
Net Income (ttm) 22.25M
Shares Out 44.52M
EPS (ttm) 0.55
PE Ratio 15.87
Forward PE 20.00
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $8.73
Previous Close $9.02
Change ($) -0.29
Change (%) -3.22%
Day's Open 8.90
Day's Range 8.72 - 8.92
Day's Volume 56,427
52-Week Range 4.40 - 10.00

More Stats

Market Cap 388.66M
Enterprise Value 320.50M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 44.52M
Float 27.36M
EPS (basic) 0.55
EPS (diluted) 0.55
FCF / Share 0.63
Dividend n/a
Dividend Yield n/a
Earnings Yield 6.30%
FCF Yield 6.50%
Payout Ratio n/a
Shares Short 133,576
Short Ratio 1.04
Short % of Float 0.82%
Beta 0.50
PE Ratio 15.87
Forward PE 20.00
P/FCF Ratio 15.37
PS Ratio 2.91
PB Ratio 2.38
Revenue 133.68M
Operating Income 22.78M
Net Income 22.25M
Free Cash Flow 25.28M
Net Cash 68.16M
Net Cash / Share 1.53
Gross Margin 37.21%
Operating Margin 17.04%
Profit Margin 17.50%
FCF Margin 18.91%
ROA 8.20%
ROE 15.92%
ROIC 23.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$10.50*
(20.27% upside)
Low
10.0
Current: $8.73
High
11.0
Target: 10.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue12711410377.4969.9171.0770.6272.6859.4834.48
Revenue Growth11.11%11.32%32.69%10.85%-1.63%0.63%-2.82%22.18%72.53%-
Gross Profit49.7441.4732.0921.3615.3715.0426.4122.6916.725.77
Operating Income22.7819.267.44-5.48-11.42-11.483.704.24-2.47-10.20
Net Income22.2522.306.90-6.73-11.27-13.210.440.26-3.72-14.42
Shares Outstanding40.3040.2636.4536.4235.9935.9634.3134.31--
Earnings Per Share0.550.550.18-0.18-0.31-0.370.010.01-0.15-0.54
EPS Growth0%205.56%----0%---
Operating Cash Flow27.5710.553.611.90-13.98-9.92-3.85-8.260.9910.04
Capital Expenditures-2.29-2.85-4.11-2.60-2.72-3.07-5.64-4.61-1.98-3.63
Free Cash Flow25.287.69-0.50-0.70-16.70-12.99-9.49-12.87-0.996.40
Cash & Equivalents73.9150.5943.0228.6328.3151.9074.1833.8042.690.00
Total Debt5.751.281.981.780.197.4916.2224.1222.44-
Net Cash / Debt68.1649.3141.0426.8628.1244.4057.969.6820.240.00
Assets17413812299.7010211913989.1185.11-
Liabilities38.4825.7432.6232.9529.4938.7249.4160.7263.01-
Book Value13511289.4966.7472.5180.4289.9728.3922.40-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kamada Ltd.
Country Israel
Employees 429
CEO Amir London

Stock Information

Ticker Symbol KMDA
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: KMDA

Description

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus, as well as human transferrin that is used as a cultural medium for diagnostic assays and cell cultures. In addition, the company distributes Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for the prevention of hepatitis B virus; Megalotect, a CMV immunoglobulin; and RUCONEST for the treatment of acute angioedema attacks in adults with hereditary angioedema. Further, it distributes Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. The company's products in pipeline are G1-AAT (IV) for graft versus host disease and L1-AAT (1V) for lung transparent that are in Phase II stage; and Inhaled AAT for AAT deficiency, which is in Phase II and III stages. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion Biopharma. The company was founded in 1990 and is headquartered in Rehovot, Israel.